BR9815786A - Quinolonas como inibidores de protease de serina - Google Patents

Quinolonas como inibidores de protease de serina

Info

Publication number
BR9815786A
BR9815786A BR9815786-8A BR9815786A BR9815786A BR 9815786 A BR9815786 A BR 9815786A BR 9815786 A BR9815786 A BR 9815786A BR 9815786 A BR9815786 A BR 9815786A
Authority
BR
Brazil
Prior art keywords
quinolones
protease inhibitors
serine protease
prodrugs
compounds
Prior art date
Application number
BR9815786-8A
Other languages
English (en)
Inventor
Danette Andrea Dudley
Jeremy John Edmunds
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BR9815786A publication Critical patent/BR9815786A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

Patente de Invenção: <B>"QUINOLONAS COMO INIBIDORES DE PROTEASE DE SERINA"<D>. A presente invenção descreve quinolinonas que apresentam efeitos inibidores em proteases de serina tal como o fator Xa, trombina e/ou fator VIIa. A invenção também descreve sais e pró-drogas farmaceuticamente aceitáveis dos compostos, composições farmaceuticamente aceitáveis que compreendem os compostos, seus sais ou pró-drogas e métodos de usá-los como agentes terapêuticos para tratamento ou prevenção de estados de doença em mamíferos caracterizado por trombose anormal.
BR9815786-8A 1998-03-31 1998-12-15 Quinolonas como inibidores de protease de serina BR9815786A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8009098P 1998-03-31 1998-03-31
PCT/US1998/026709 WO1999050263A1 (en) 1998-03-31 1998-12-15 Quinolones as serine protease inhibitors

Publications (1)

Publication Number Publication Date
BR9815786A true BR9815786A (pt) 2000-11-21

Family

ID=22155200

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9815786-8A BR9815786A (pt) 1998-03-31 1998-12-15 Quinolonas como inibidores de protease de serina

Country Status (15)

Country Link
US (1) US6855726B1 (pt)
EP (1) EP1091955A1 (pt)
JP (1) JP2002509928A (pt)
KR (1) KR20010042287A (pt)
AU (1) AU763110B2 (pt)
BR (1) BR9815786A (pt)
CA (1) CA2312953A1 (pt)
HU (1) HUP0101484A3 (pt)
IL (1) IL136605A0 (pt)
IS (1) IS5553A (pt)
NO (1) NO20004696D0 (pt)
NZ (1) NZ505921A (pt)
PL (1) PL343112A1 (pt)
WO (1) WO1999050263A1 (pt)
ZA (1) ZA992448B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291514B1 (en) 1998-02-09 2001-09-18 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors
PL351767A1 (en) * 1999-02-09 2003-06-16 Dimensional Pharmaceuticals 3 Heteroaryl amidines, methylamidines and guanidines as protease inhibitors
US7323496B2 (en) 1999-11-08 2008-01-29 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
KR20010069066A (ko) * 2000-01-12 2001-07-23 이종원 저산소 농도하에서 생존이 가능하도록 하는 동물세포의배양방법
AU779442B2 (en) * 2000-01-20 2005-01-27 Eisai Co. Ltd. Novel piperidine compounds and drugs containing the same
KR100784958B1 (ko) * 2000-02-04 2007-12-11 테라코스, 인코포레이티드 신규한 디페닐에틸렌 화합물
DE60137020D1 (de) * 2000-02-04 2009-01-29 Theracos Inc Neue diphenylethylene-verbindungen
MXPA03000289A (es) 2000-08-04 2003-06-06 Warner Lambert Co Proceso para preparar 2-(4-piridil) amino-6-dialquiloxifenil-pirido (2,3-d) pirimidin-7-onas..
US6756383B2 (en) 2000-09-01 2004-06-29 Chiron Corporation Heterocyclic derivatives of quinolinone benimidazoles
MXPA03002032A (es) 2000-09-11 2003-07-24 Chiron Corp Derivados de quinolinona.
FR2813791B1 (fr) * 2000-09-14 2004-03-12 Lafon Labor Utilisation de 2- et 4-quinolones pour inhiber la neo-proliferation intimale
CA2496164C (en) 2002-08-23 2010-11-09 Chiron Corporation Benzimidazole quinolinones and uses thereof
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
JP2006511616A (ja) 2002-11-13 2006-04-06 カイロン コーポレイション 癌の処置方法およびその関連方法
JP4744149B2 (ja) 2002-12-03 2011-08-10 ファーマサイクリックス インコーポレイテッド 第ｖｉｉａ因子阻害剤としての２−（２−ヒドロキシビフェニル−３−イル）−１ｈ−ベンゾイミダゾール−５−カルボキサミジン誘導体
TWI289141B (en) 2003-03-11 2007-11-01 Hoffmann La Roche F. Ag. Quinolinone derivatives and uses thereof
AR047521A1 (es) * 2004-02-06 2006-01-25 Astrazeneca Ab Compuestos piridin-2-ona utiles como inhibidores de trombina
BRPI0507891A (pt) 2004-02-20 2007-07-24 Chiron Corp modulação dos processos inflamatório e metastático
EP1799639B1 (en) 2004-10-12 2013-09-04 Glenmark Pharmaceuticals S.A. Novel dipeptidyl peptidase iv inhibitors, pharmaceutical compositions containing them, and process for their preparation
US7960548B2 (en) * 2005-04-29 2011-06-14 The Ohio State University Research Foundation Keratinocyte growth factor receptor—tyrosine specific inhibitors for the prevention of cancer metastatis
EP2591784B1 (en) 2005-05-10 2016-09-14 Intermune, Inc. Pyridine-2-one-derivatives as modulators of stress-activated protein kinase system
EP1888556B1 (en) 2005-05-17 2011-10-26 Novartis AG Methods for synthesizing heterocyclic compounds
BRPI0611375A2 (pt) 2005-05-23 2010-08-31 Novartis Ag formas cristalinas e outras de sais de ácido láctico de 4-amino-5-flúor-3-[6-(4-metilpiperazin-1-il)-1h-benzimid azol-2-il]-1h-quinolin-2-ona
GB0515323D0 (en) * 2005-07-26 2005-08-31 Electrophoretics Ltd Mass labels
CA2726588C (en) 2008-06-03 2019-04-16 Karl Kossen Compounds and methods for treating inflammatory and fibrotic disorders
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
MX2016012808A (es) 2014-04-02 2017-01-05 Intermune Inc Piridinonas anti-fibroticas.
EP3642184A1 (en) * 2017-06-22 2020-04-29 Curadev Pharma Limited Small molecule modulators of human sting
UA125730C2 (uk) 2017-06-22 2022-05-25 Курадев Фарма Лімітед Низькомолекулярні модулятори sting людини

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3330823A (en) 1964-12-16 1967-07-11 Squibb & Sons Inc N-amino-loweralkylene-benzo-lactams
US3551413A (en) 1969-03-12 1970-12-29 Squibb & Sons Inc Benzo-lactams
GB1305278A (pt) 1970-03-12 1973-01-31
JPS5310989B2 (pt) 1974-04-25 1978-04-18
US4070470A (en) * 1974-06-24 1978-01-24 Otsuka Pharmaceutical Co., Ltd. Platelet aggregation inhibiting carbostyrils, their compositions and method of use
US4329347A (en) * 1978-02-17 1982-05-11 Boehringer Ingelheim Gmbh Cardiotonic and antithrombotic sulfur-containing derivatives of carbostyril
FR2439196A1 (fr) * 1978-10-17 1980-05-16 Yoshitomi Pharmaceutical Nouveaux derives de la pyridazinone utilisables en therapeutique comme agents anti-thrombotiques et anti-hypertenseurs
EP0024638A1 (en) 1979-08-30 1981-03-11 Byk Gulden Lomberg Chemische Fabrik GmbH Substituted quinolinone-alkanecarboxylic acids, their preparation, and medicaments containing them
JPS5649359A (en) 1979-09-28 1981-05-02 Otsuka Pharmaceut Co Ltd Carbostyril derivative
JPS56125388A (en) 1980-03-08 1981-10-01 Yuichi Kaneoka Dihydrobenzofuran derivative
DE3810080A1 (de) 1988-03-25 1989-10-05 Bayer Ag Trisubstituierte 1,3,5-triazin-2,4,6-trione
HUT76640A (en) 1995-08-17 1997-10-28 Chinoin Gyogyszer Es Vegyeszet Compounds of pharmaceutical activity cyclic amide derivatives, pharmaceutical compositions containing them, process for producing them and their use
TW338037B (en) * 1995-10-05 1998-08-11 Otsuka Pharma Co Ltd Carbostyril derivatives possessing platelet aggregation inhibitory activity, antithrombotic activity, intima thinkening, inhibitory activity and phosphoriesterase inhibitory activity, their preparation and pharmaceutical composition
DE19610723A1 (de) 1996-03-19 1997-09-25 Bayer Ag Elektrolumineszierende Anordnungen unter Verwendung von Blendsystemen
DE19718181A1 (de) * 1997-04-30 1998-11-05 Boehringer Ingelheim Pharma Disubstituierte bicyclische Heterocyclen, ihre Herstellung und ihre Verwendung als Arzneimittel

Also Published As

Publication number Publication date
KR20010042287A (ko) 2001-05-25
US6855726B1 (en) 2005-02-15
AU763110B2 (en) 2003-07-10
IS5553A (is) 2000-06-28
WO1999050263A1 (en) 1999-10-07
IL136605A0 (en) 2001-06-14
NO20004696L (no) 2000-09-20
HUP0101484A3 (en) 2003-02-28
ZA992448B (en) 2000-10-11
HUP0101484A2 (hu) 2001-10-28
NO20004696D0 (no) 2000-09-20
NZ505921A (en) 2003-08-29
JP2002509928A (ja) 2002-04-02
CA2312953A1 (en) 1999-10-07
AU1918499A (en) 1999-10-18
PL343112A1 (en) 2001-07-30
EP1091955A1 (en) 2001-04-18

Similar Documents

Publication Publication Date Title
BR9815786A (pt) Quinolonas como inibidores de protease de serina
BR9815785A (pt) Quinoxalinonas como inibidores de protease de serina tal como fator xa e trombina
BR9815784A (pt) Benzoxazinonas/benzotiazinonas como inibidores de protease de serina
UY27558A1 (es) Inhibidores del factor xa y de otras proteasas de serina implicadas en la cascada de la coagulación
BR9812699A (pt) Derivados de benzamidina
BR0205889A (pt) Pirazolopirimidinas como agentes tepapêuticos
BR0008755A (pt) compostos inibidores de protease de serina, composição, método de inibição da atividade de tf/fator viia, fator xa, trombina ou calicreìna, método de tratamento de uma disfunção mediada por tf/fator viia, fator xa, trombina ou calicreìna e método de prevenção de trombose ou tratamento de trombose anormal
BR0208387A (pt) Derivados de imidazo (1,2-a)-piridina como antagonista de mglur5
DE69526677T2 (de) Aromatische heterocyclische derivate als enzyminhibitoren
BR0115861A (pt) Composto, derivado farmaceuticamente aceitável de um composto, formulação farmacêutica, uso de um composto, métodos de tratamento de uma condição onde a inibição da trombina é requerida e de uma condição onde a terapia anticoagulante é indicada, e, processo para a preparação de um composto
BR0014602A (pt) Hexaidrofluoro&#39;2,3-bifuran-3-il-n-{3&#39;(1,3-benzodioxol- 5ilsulfonil)(isobutil)amino-1 -benzil-2-hidroxipropil}carbamato como inibidor da protease retroviral
BR0116804A (pt) Derivados fenìlicos
DE60115394D1 (de) Benzamide und ähnliche inhibitoren vom faktor xa
SI1509232T1 (sl) Kombinacija antagonista nmda in zaviralcev acetilholinesteraze za zdravljenje alzheimerjeve bolezni
DE69716823T2 (de) Thrombin-Inhibitoren als anticoagulierende Mittel
WO2001044172A8 (en) Salicylamides as serine protease and factor xa inhibitors
BRPI0507818A (pt) composto e métodos de inibição
HRP20070552T3 (en) Combination of mglur2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders
BRPI0418384A (pt) composições farmacêuticas e métodos referentes à inibição de adesões fibrosas utilizando diversos agentes
TR199801705T2 (xx) Serin proteaz inhibit�rleri.
BR0210531A (pt) Derivados de ácido sulfÈnico
TR199801704T2 (xx) Serin proteaz inhibit�rleri.
BR0210912A (pt) Compostos e composições como inibidores de catepsina
BR0112580A (pt) Compostos, composições farmacêuticas que contêm os mesmos, utilização desses compostos, processo para tratamento terapêutico e/ou profilático e processo para a preparação desses compostos
BR9813719A (pt) Agentes terapêuticos

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL.8: A61K 31/4704, C07D 401/00, A61P 7/02

Ipc: A61K 31/4704 (2007.10), C07D 401/00 (2007.10), A61

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 8O DA LPI.